← Back to Screener
Penumbra, Inc. (PEN)
Price$318.95
Value ScoreF
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-2.17%
Price vs S&P 500 (4W)-7.13%
VGM Score44.00
Market Capitalization$12.52B
P/E Ratio (Annual)70.46x
All Metrics
P/CF (Annual)52.46x
Book Value / Share (Quarterly)$37.48
P/TBV (Annual)8.57x
Revenue Growth (3Y)18.33%
Cash Flow / Share (Quarterly)$5.41
Price vs S&P 500 (YTD)-8.56%
Gross Margin (TTM)67.38%
Net Profit Margin (TTM)11.76%
EPS (TTM)$4.35
10-Day Avg Trading Volume0.46M
EPS Excl Extra (TTM)$4.35
Revenue Growth (5Y)20.16%
EPS (Annual)$4.52
ROI (Annual)12.25%
Gross Margin (Annual)67.14%
Net Profit Margin (5Y Avg)4.58%
Cash / Share (Quarterly)$15.66
P/E Basic Excl Extra (TTM)73.19x
Revenue Growth QoQ (YoY)15.62%
EPS Growth (5Y)-23.21%
P/E Normalized (Annual)70.46x
ROA (Last FY)9.73%
Revenue Growth TTM (YoY)17.27%
EBITD / Share (TTM)$4.76
ROE (5Y Avg)4.35%
Operating Margin (TTM)12.87%
Cash Flow / Share (Annual)$4.46
P/B Ratio8.49x
P/B Ratio (Quarterly)8.76x
Net Income / Employee (Annual)$37,800
EV / Revenue (TTM)8.46x
ROA (TTM)9.58%
EPS Growth QoQ (YoY)-17.72%
EV / EBITDA (TTM)65.57x
EPS Incl Extra (Annual)$4.52
Current Ratio (Annual)6.64x
Quick Ratio (Quarterly)3.77x
3-Month Avg Trading Volume0.68M
52-Week Price Return19.87%
EV / Free Cash Flow (Annual)70.32x
P/E Incl Extra (TTM)73.19x
Revenue / Employee (TTM)$309,400
Tangible BV / Share (Quarterly)$37.33
P/S Ratio (Annual)8.92x
Asset Turnover (Annual)0.77x
52-Week High$362.41
Operating Margin (5Y Avg)4.19%
EPS Excl Extra (Annual)$4.52
CapEx CAGR (5Y)20.81%
Tangible BV CAGR (5Y)17.64%
26-Week Price Return13.76%
Quick Ratio (Annual)4.01x
13-Week Price Return-6.91%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)6.02x
Enterprise Value$12.30B
Revenue / Share Growth (5Y)17.94%
Asset Turnover (TTM)0.81x
Book Value / Share Growth (5Y)15.61%
Revenue / Employee (Annual)$298,700
Inventory Turnover (Annual)1.10x
Pretax Margin (Annual)14.61%
Cash / Share (Annual)$13.89
3-Month Return Std Dev9.79%
Gross Margin (5Y Avg)64.32%
Net Income / Employee (TTM)$36,400
EBITDA CAGR (5Y)-22.08%
EBITDA Interim CAGR (5Y)22.86%
ROE (Last FY)12.45%
EPS Basic Excl Extra (Annual)$4.52
P/FCF (TTM)58.85x
Receivables Turnover (TTM)8.28x
EV / Free Cash Flow (TTM)57.82x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$4.35
Receivables Turnover (Annual)7.85x
ROI (TTM)12.11%
P/S Ratio (TTM)8.61x
Pretax Margin (5Y Avg)4.59%
Revenue / Share (Annual)$35.72
Tangible BV / Share (Annual)$36.23
Forward P/E65.09x
Free OCF CAGR (5Y)100.55%
Price vs S&P 500 (52W)-8.33%
P/E Ratio (TTM)73.19x
EPS Growth TTM (YoY)323.55%
Year-to-Date Return2.38%
5-Day Price Return-3.16%
EPS Normalized (Annual)$4.52
ROA (5Y Avg)3.35%
Net Profit Margin (Annual)12.66%
Month-to-Date Return-2.51%
Cash Flow / Share (TTM)$1.73
EBITD / Share (Annual)$4.83
EPS Growth (3Y)36.66%
Operating Margin (Annual)13.48%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)45.25x
ROI (5Y Avg)4.27%
P/E Excl Extra (TTM)73.19x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$4.35
P/TBV (Quarterly)8.80x
P/B Ratio (Annual)8.53x
Inventory Turnover (TTM)1.11x
Pretax Margin (TTM)13.96%
Book Value / Share (Annual)$36.39
Price vs S&P 500 (13W)-16.66%
Net Margin Growth (5Y)-33.30%
Beta0.70x
P/FCF (Annual)71.57x
Revenue / Share (TTM)$36.78
ROE (TTM)12.32%
52-Week Low$221.26
vGradeF
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.82est. 1.09
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.48
3.48
3.50
3.50
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PENPenumbra, Inc. | F | C | C | $318.95 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| GMEDGLOBUS MEDICAL INC | B | A | C | $79.78 |
About
US-based Penumbra manufactures minimally invasive medical devices for mechanical removal of blood clots in acute care settings. The company's thrombectomy and embolization devices address stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular conditions, sold primarily to hospitals and physicians.